NORCROSS, Ga., Jan. 25, 2006 (PRIMEZONE) -- Auriga Pharmaceuticals, LLC, a specialty pharmaceutical company led by a team of noted scientists and industry executives, has launched a national sales force to market and sell specialty pharmaceutical products, including its flagship product line, Extendryl(r).
The national team is comprised of 40 sales representatives with significant experience in marketing and selling prescription pharmaceutical products to physicians, physician assistants and nurse practitioners. Four regional sales mangers and a vice president of sales manage the national team under the direction of Andrew D. Shales, Auriga's senior vice president of sales and marketing.
"The launch and training of our national sales force delivers a strong presence in all of our key markets in the United States," said Guy Amato, Auriga CEO. "The formal launch of this team, combined with intensive training provided here at our commercial headquarters this month, signals another major milestone taken in establishing the Auriga business."
The team will sell Auriga's promoted prescription products nationally, including seven products currently available in the Extendryl line, a cough and cold medication prescribed to relieve the symptoms of colds, as well seasonal and perennial allergies.
"We have a mature group of sales professionals with a great deal of experience in the pharmaceutical industry," said Shales. "Collectively, these seasoned representatives make up a high-quality sales team providing national coverage for Auriga products. They will be marketing and selling primarily to allergists, pediatricians and a select group of primary care doctors, as well as nurse practitioners and physician assistants."
The Extendryl line offers seven products (Extendryl HC, Extendryl PSE, Extendryl DM, Extendryl Seniors, Extendryl Juniors, Extendryl Chewables and Extendryl Syrup).
Auriga has been established to develop new applications and drug delivery technologies for existing prescription drugs where significant clinical value can be added to benefit patients, particularly children and the elderly.
About Auriga
Auriga Pharmaceuticals, LLC is a wholly-owned subsidiary of Auriga Laboratories, Inc., which develops and markets new prescription products for approved drugs using proprietary drug delivery technologies and reformulation strategies. The specialty pharmaceutical company is based in Norcross, Georgia. A highly integrated team of experienced pharmaceutical industry executives manages product life cycle from development through marketing and sales. The company currently markets Extendryl(r), a prescription cough/cold medication. More information is available at the company's website at: http://www.aurigalabs.com.